Dermira Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
June 13, 2016 16:05 ET
|
Dermira, Inc.
MENLO PARK, Calif., June 13, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
Dermira Prices $126 Million Public Offering of Common Stock
June 08, 2016 07:00 ET
|
Dermira, Inc.
MENLO PARK, Calif., June 08, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
Dermira to Present Preclinical Data from DRM01 Acne Program at the Society for Investigative Dermatology 75th Annual Meeting
May 11, 2016 16:05 ET
|
Dermira, Inc.
MENLO PARK, Calif., May 11, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
Dermira Reports First Quarter 2016 Financial Results and Provides Corporate Update
May 10, 2016 06:30 ET
|
Dermira, Inc.
- Positive Topline Results for DRM01 Phase 2b Acne Trial Reported; Phase 3 Program Planning Underway - Announcement of Topline Results for DRM04 Phase 3 Hyperhidrosis Pivotal Trials Expected in...
Dermira Announces Positive Topline Phase 2b Clinical Trial Results for DRM01 in Patients with Facial Acne Vulgaris
May 10, 2016 06:00 ET
|
Dermira, Inc.
- Safety and Efficacy Data Confirm Results from Previous Phase 2a Trial - DRM01 Phase 3 Clinical Program Planning Underway - Management to Host Webcast and Conference Call Today at 5:30 a.m....
Dermira’s Co-founder and Chief Medical Officer, Eugene A. Bauer, M.D., Receives Presidential Citation from the American Academy of Dermatology
March 14, 2016 07:30 ET
|
Dermira, Inc.
MENLO PARK, Calif., March 14, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
Dermira Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update
March 03, 2016 07:30 ET
|
Dermira, Inc.
MENLO PARK, Calif., March 03, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
Dermira Elects Kathleen Sebelius to Board of Directors
September 30, 2015 16:05 ET
|
Dermira, Inc.
MENLO PARK, Calif., Sept. 30, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists...
Dermira to Present Data for DRM01 Acne Program at EADV Congress 2015
September 29, 2015 16:05 ET
|
Dermira, Inc.
MENLO PARK, Calif., Sept. 29, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists...
Skin Disposition Study Results for Dermira's DRM01 Program in Acne Presented at International Dermatology Meeting
September 10, 2015 07:30 ET
|
Dermira, Inc.
MENLO PARK, Calif., Sept. 10, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists...